Comparison of montelukast and intranasal antihistamine in allergic rhinitis treatment

Phase 3

Recruiting

• Conditions: Allergic rhinitis.; Allergic rhinitis, unspecified; J30.9

• Registration Number: IRCT20200906048642N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Moderate to severe allergic rhinitis
Seasonal and perennial allergic rhinitis

Exclusion Criteria

Mild or intermittent allergic rhinitis
Chronic diseases under treatment(chronic kidney disease,hypertension,diabetes mellitus)
History of drug reaction
Immunotherapy
Infectious rhinosinusitis

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of life via SNOT22. Timepoint: Monthly up to 3 months. Method of measurement: SNOT22 questionnaire.

Secondary Outcome Measures

Name	Time	Method
Patient symptoms. Timepoint: Monthly to 3 months. Method of measurement: SNOT22 questionnaire.